Dabigatran-induced upper intestinal bleeding in a patient with chronic kidney disease.
José J
JJ
Ribés-Cruz
Isidro
I
Torregrosa-Maicas
Carmela
C
Ramos-Tomás
Miguel A
MA
Solís-Salguero
M José
MJ
Puchades-Montesa
Miguel A
MA
González-Rico
Isabel
I
Juan-García
Patricia
P
Tomás-Simó
Sandra
S
Tejedor-Alonso
Patricia
P
Zambrano-Esteves
Alfonso
A
Miguel-Carrasco
D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000150:complications; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069604:Dabigatran; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D017707:Erythrocyte Transfusion; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications; D008657:Metabolic Clearance Rate; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000378:metabolism / Q000628:therapy; D019851:Thrombophilia / Q000188:drug therapy* / Q000209:etiology; D014552:Urinary Tract Infections / Q000150:complications; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use
D001562:Benzimidazoles; D015091:beta-Alanine; D000069604:Dabigatran